Skip to main content
Top
Published in: Osteoporosis International 4/2013

01-04-2013 | Original Article

Hip fracture and other predictors of anti-osteoporosis drug use in Norway

Authors: H. M. Devold, A. J. Søgaard, A. Tverdal, J. A. Falch, K. Furu, H. E. Meyer

Published in: Osteoporosis International | Issue 4/2013

Login to get access

Abstract

Summary

This study aims to find predictors of anti-osteoporosis drug (AOD) use. Known risk factors of osteoporosis, i.e., age, hip fracture, and corticosteroid use were found to be predictors of AOD use, in addition to a number of other drugs used. Higher socioeconomic position did not favor the use of AOD.

Introduction

This study deals with studying predictors of anti-osteoporosis drug treatment in Norwegian women and men.

Methods

All Norwegian women and men ≥50 years were included (n = 1,407,392). Data were taken from different data sources, (1) the Norwegian Prescription Database (drug use in 2004–2005); (2) the Nationwide Census 2001 (marital status, education and resident county); (3) the National Hip Fracture Database (hip fractures 2003–2005); and (4) the National Population Register (date of death/emigration). We estimated the hazard ratios (HR) for incident treatment by Cox proportional hazard regression.

Results

In 2005, 10,332 women (1.5 %) and 1,387 men (0.2 %) were new users of anti-osteoporosis drugs (incident treatment). Age was a statistically significant predictor of incident treatment in both women and men, with HR ranging from 1.7 to 3.2 (per 10 years). A middle educational level in men strongly predicted incident treatment [HR 2.0 (CI 1.1–3.8)], but not in women after full adjustment. A previous hip fracture, increasing number of drugs used and use of corticosteroids were all predictors of incident treatment in both genders after adjustments. Corticosteroid use [HRwomen = 4.0 (CI 3.8–4.2)] had a higher HR for incident treatment than hip fracture [HRwomen = 2.0 (CI 1.8–2.3)]. Marital status and area of residency were not predictors of incident treatment in either gender, after adjustments. The predictors of prevalent treatment were only slightly different from incident treatment in 2005.

Conclusions

Age, previous hip fracture, number of drugs used, and use of corticosteroids were positively related to treatment in both genders. In men, a middle educational level predicted treatment.
Literature
1.
go back to reference Falch JA, Meyer HE (1998) Osteoporosis and fractures in Norway. Occurrence and risk factors. Tidsskr Nor Laegeforen 118:568–572PubMed Falch JA, Meyer HE (1998) Osteoporosis and fractures in Norway. Occurrence and risk factors. Tidsskr Nor Laegeforen 118:568–572PubMed
2.
go back to reference Lofthus CM, Osnes EK, Falch JA, Kaastad TS, Kristiansen IS, Nordsletten L, Stensvold I, Meyer HE (2001) Epidemiology of hip fractures in Oslo, Norway. Bone 29:413–418PubMedCrossRef Lofthus CM, Osnes EK, Falch JA, Kaastad TS, Kristiansen IS, Nordsletten L, Stensvold I, Meyer HE (2001) Epidemiology of hip fractures in Oslo, Norway. Bone 29:413–418PubMedCrossRef
3.
go back to reference Lunt M, Felsenberg D, Adams J, Benevolenskaya L, Cannata J, Dequeker J, Dodenhof C, Falch JA, Johnell O, Khaw KT, Masaryk P, Pols H, Poor G, Reid D, Scheidt-Nave C, Weber K, Silman AJ, Reeve J (1997) Population-based geographic variations in DXA bone density in Europe: the EVOS Study. European Vertebral Osteoporosis. Osteoporos Int 7:175–189PubMedCrossRef Lunt M, Felsenberg D, Adams J, Benevolenskaya L, Cannata J, Dequeker J, Dodenhof C, Falch JA, Johnell O, Khaw KT, Masaryk P, Pols H, Poor G, Reid D, Scheidt-Nave C, Weber K, Silman AJ, Reeve J (1997) Population-based geographic variations in DXA bone density in Europe: the EVOS Study. European Vertebral Osteoporosis. Osteoporos Int 7:175–189PubMedCrossRef
4.
go back to reference O’Neill TW, Felsenberg D, Varlow J, Cooper C, Kanis JA, Silman AJ (1996) The prevalence of vertebral deformity in European men and women: the European Vertebral Osteoporosis Study. J Bone Miner Res 11:1010–1018PubMedCrossRef O’Neill TW, Felsenberg D, Varlow J, Cooper C, Kanis JA, Silman AJ (1996) The prevalence of vertebral deformity in European men and women: the European Vertebral Osteoporosis Study. J Bone Miner Res 11:1010–1018PubMedCrossRef
5.
go back to reference Boonen S, Autier P, Barette M, Vanderschueren D, Lips P, Haentjens P (2004) Functional outcome and quality of life following hip fracture in elderly women: a prospective controlled study. Osteoporos Int 15:87–94PubMedCrossRef Boonen S, Autier P, Barette M, Vanderschueren D, Lips P, Haentjens P (2004) Functional outcome and quality of life following hip fracture in elderly women: a prospective controlled study. Osteoporos Int 15:87–94PubMedCrossRef
6.
go back to reference Cooper C (1997) The crippling consequences of fractures and their impact on quality of life. Am J Med 103:12S–17SPubMedCrossRef Cooper C (1997) The crippling consequences of fractures and their impact on quality of life. Am J Med 103:12S–17SPubMedCrossRef
7.
go back to reference Forsen L, Sogaard AJ, Meyer HE, Edna T, Kopjar B (1999) Survival after hip fracture: short- and long-term excess mortality according to age and gender. Osteoporos Int 10:73–78PubMedCrossRef Forsen L, Sogaard AJ, Meyer HE, Edna T, Kopjar B (1999) Survival after hip fracture: short- and long-term excess mortality according to age and gender. Osteoporos Int 10:73–78PubMedCrossRef
8.
go back to reference Johnell O, Kanis JA, Jonsson B, Oden A, Johansson H, De LC (2005) The burden of hospitalised fractures in Sweden. Osteoporos Int 16:222–228PubMedCrossRef Johnell O, Kanis JA, Jonsson B, Oden A, Johansson H, De LC (2005) The burden of hospitalised fractures in Sweden. Osteoporos Int 16:222–228PubMedCrossRef
9.
go back to reference Osnes EK, Lofthus CM, Meyer HE, Falch JA, Nordsletten L, Cappelen I, Kristiansen IS (2004) Consequences of hip fracture on activities of daily life and residential needs. Osteoporos Int 15:567–574PubMedCrossRef Osnes EK, Lofthus CM, Meyer HE, Falch JA, Nordsletten L, Cappelen I, Kristiansen IS (2004) Consequences of hip fracture on activities of daily life and residential needs. Osteoporos Int 15:567–574PubMedCrossRef
10.
go back to reference Johnell O, Kanis JA (2006) An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 17:1726–1733PubMedCrossRef Johnell O, Kanis JA (2006) An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 17:1726–1733PubMedCrossRef
11.
go back to reference Bliuc D, Ong CR, Eisman JA, Center JR (2005) Barriers to effective management of osteoporosis in moderate and minimal trauma fractures: a prospective study. Osteoporos Int 16:977–982PubMedCrossRef Bliuc D, Ong CR, Eisman JA, Center JR (2005) Barriers to effective management of osteoporosis in moderate and minimal trauma fractures: a prospective study. Osteoporos Int 16:977–982PubMedCrossRef
12.
go back to reference Eisman J, Clapham S, Kehoe L, Australian BS (2004) Osteoporosis prevalence and levels of treatment in primary care: the Australian BoneCare Study. J Bone Miner Res 19:1969–1975PubMedCrossRef Eisman J, Clapham S, Kehoe L, Australian BS (2004) Osteoporosis prevalence and levels of treatment in primary care: the Australian BoneCare Study. J Bone Miner Res 19:1969–1975PubMedCrossRef
13.
go back to reference Colon-Emeric C, Lyles KW, Levine DA, House P, Schenck A, Gorospe J, Fermazin M, Oliver K, Alison J, Weisman N, Xie A, Curtis JR, Saag K (2007) Prevalence and predictors of osteoporosis treatment in nursing home residents with known osteoporosis or recent fracture. Osteoporos Int 18:553–559PubMedCrossRef Colon-Emeric C, Lyles KW, Levine DA, House P, Schenck A, Gorospe J, Fermazin M, Oliver K, Alison J, Weisman N, Xie A, Curtis JR, Saag K (2007) Prevalence and predictors of osteoporosis treatment in nursing home residents with known osteoporosis or recent fracture. Osteoporos Int 18:553–559PubMedCrossRef
14.
go back to reference Luthje P, Nurmi-Luthje I, Kaukonen JP, Kuurne S, Naboulsi H, Kataja M (2009) Undertreatment of osteoporosis following hip fracture in the elderly. Arch Gerontol Geriatr 49:153–157PubMedCrossRef Luthje P, Nurmi-Luthje I, Kaukonen JP, Kuurne S, Naboulsi H, Kataja M (2009) Undertreatment of osteoporosis following hip fracture in the elderly. Arch Gerontol Geriatr 49:153–157PubMedCrossRef
15.
go back to reference Panneman MJ, Lips P, Sen SS, Herings RM (2004) Undertreatment with anti-osteoporotic drugs after hospitalization for fracture. Osteoporos Int 15:120–124PubMedCrossRef Panneman MJ, Lips P, Sen SS, Herings RM (2004) Undertreatment with anti-osteoporotic drugs after hospitalization for fracture. Osteoporos Int 15:120–124PubMedCrossRef
16.
go back to reference Solomon DH, Morris C, Cheng H, Cabral D, Katz JN, Finkelstein JS, Avorn J (2005) Medication use patterns for osteoporosis: an assessment of guidelines, treatment rates, and quality improvement interventions. Mayo Clin Proc 80:194–202PubMedCrossRef Solomon DH, Morris C, Cheng H, Cabral D, Katz JN, Finkelstein JS, Avorn J (2005) Medication use patterns for osteoporosis: an assessment of guidelines, treatment rates, and quality improvement interventions. Mayo Clin Proc 80:194–202PubMedCrossRef
17.
go back to reference Devold HM, Doung GM, Tverdal A, Furu K, Meyer HE, Falch JA, Sogaard AJ (2010) Prescription of anti-osteoporosis drugs during 2004–2007—a nationwide register study in Norway. Eur J Clin Pharmacol 66:299–306PubMedCrossRef Devold HM, Doung GM, Tverdal A, Furu K, Meyer HE, Falch JA, Sogaard AJ (2010) Prescription of anti-osteoporosis drugs during 2004–2007—a nationwide register study in Norway. Eur J Clin Pharmacol 66:299–306PubMedCrossRef
18.
go back to reference Sosial- og helsedirektoratet (2005) Faglige retningslinjer for forebygging og behandling av osteoporose og osteoporotiske brudd. Sosial-og helsedirektoratet, Oslo Sosial- og helsedirektoratet (2005) Faglige retningslinjer for forebygging og behandling av osteoporose og osteoporotiske brudd. Sosial-og helsedirektoratet, Oslo
19.
go back to reference Asche C, Nelson R, McAdam-Marx C, Jhaveri M, Ye X (2010) Predictors of oral bisphosphonate prescriptions in post-menopausal women with osteoporosis in a real-world setting in the USA. Osteoporos Int 21:1427–1436PubMedCrossRef Asche C, Nelson R, McAdam-Marx C, Jhaveri M, Ye X (2010) Predictors of oral bisphosphonate prescriptions in post-menopausal women with osteoporosis in a real-world setting in the USA. Osteoporos Int 21:1427–1436PubMedCrossRef
20.
go back to reference Cranney A, Tsang JF, Leslie WD (2009) Factors predicting osteoporosis treatment initiation in a regionally based cohort. Osteoporos Int 20:1621–1625PubMedCrossRef Cranney A, Tsang JF, Leslie WD (2009) Factors predicting osteoporosis treatment initiation in a regionally based cohort. Osteoporos Int 20:1621–1625PubMedCrossRef
21.
go back to reference Onder G, Pedone C, Gambassi G, Landi F, Cesari M, Bernabei R (2001) Treatment of osteoporosis among older adults discharged from hospital in Italy. Eur J Clin Pharmacol 57:599–604PubMedCrossRef Onder G, Pedone C, Gambassi G, Landi F, Cesari M, Bernabei R (2001) Treatment of osteoporosis among older adults discharged from hospital in Italy. Eur J Clin Pharmacol 57:599–604PubMedCrossRef
22.
go back to reference Furu K, Wettermark B, Andersen M, Martikainen JE, Almarsdottir AB, Sorensen HT (2010) The Nordic countries as a cohort for pharmacoepidemiological research. Basic Clin Pharmacol Toxicol 106:86–94PubMedCrossRef Furu K, Wettermark B, Andersen M, Martikainen JE, Almarsdottir AB, Sorensen HT (2010) The Nordic countries as a cohort for pharmacoepidemiological research. Basic Clin Pharmacol Toxicol 106:86–94PubMedCrossRef
23.
go back to reference WHO Collaborating Centre for Drug Statistics Methodology (2009) Guildelines for ATC classification and DDD assignment 2009. Norwegian Institute of Public Health, Oslo WHO Collaborating Centre for Drug Statistics Methodology (2009) Guildelines for ATC classification and DDD assignment 2009. Norwegian Institute of Public Health, Oslo
29.
go back to reference Roerholt C, Eiken P, Abrahamsen B (2009) Initiation of anti-osteoporotic therapy in patients with recent fractures: a nationwide analysis of prescription rates and persistence. Osteoporos Int 20:299–307PubMedCrossRef Roerholt C, Eiken P, Abrahamsen B (2009) Initiation of anti-osteoporotic therapy in patients with recent fractures: a nationwide analysis of prescription rates and persistence. Osteoporos Int 20:299–307PubMedCrossRef
30.
go back to reference Cadarette SM, Katz JN, Brookhart MA, Levin R, Stedman MR, Choudhry NK, Solomon DH (2008) Trends in drug prescribing for osteoporosis after hip fracture, 1995–2004. J Rheumatol 35:319–326PubMed Cadarette SM, Katz JN, Brookhart MA, Levin R, Stedman MR, Choudhry NK, Solomon DH (2008) Trends in drug prescribing for osteoporosis after hip fracture, 1995–2004. J Rheumatol 35:319–326PubMed
31.
go back to reference Beaupre LA, Morrish DW, Hanley DA, Maksymowych WP, Bell NR, Juby AG, Majumdar SR (2011) Oral bisphosphonates are associated with reduced mortality after hip fracture. Osteoporos Int 22:983–991PubMedCrossRef Beaupre LA, Morrish DW, Hanley DA, Maksymowych WP, Bell NR, Juby AG, Majumdar SR (2011) Oral bisphosphonates are associated with reduced mortality after hip fracture. Osteoporos Int 22:983–991PubMedCrossRef
32.
go back to reference Maggi S, Siviero P, Gonnelli S, Caffarelli C, Gandolini G, Cisari C, Rossini M, Iolascon G, Mauro GL, Nuti R, Crepaldi G (2011) The burden of previous fractures in hip fracture patients. The Break Study. Aging Clin Exp Res 23:183–186PubMed Maggi S, Siviero P, Gonnelli S, Caffarelli C, Gandolini G, Cisari C, Rossini M, Iolascon G, Mauro GL, Nuti R, Crepaldi G (2011) The burden of previous fractures in hip fracture patients. The Break Study. Aging Clin Exp Res 23:183–186PubMed
33.
go back to reference McLellan AR, Wolowacz SE, Zimovetz EA, Beard SM, Lock S, McCrink L, Adekunle F, Roberts D (2011) Fracture liaison services for the evaluation and management of patients with osteoporotic fracture: a cost-effectiveness evaluation based on data collected over 8 years of service provision. Osteoporos Int 22:2083–2098PubMedCrossRef McLellan AR, Wolowacz SE, Zimovetz EA, Beard SM, Lock S, McCrink L, Adekunle F, Roberts D (2011) Fracture liaison services for the evaluation and management of patients with osteoporotic fracture: a cost-effectiveness evaluation based on data collected over 8 years of service provision. Osteoporos Int 22:2083–2098PubMedCrossRef
34.
go back to reference Compston J, Cooper A, Cooper C, Francis R, Kanis JA, Reid DM, Selby P, Wilkins M (2010) Guideline for the diagnosis and management of osteoporosis in postmenopausal women and men of 50 years in the UK. National Osteoporosis Guideline Group (NOGG) Compston J, Cooper A, Cooper C, Francis R, Kanis JA, Reid DM, Selby P, Wilkins M (2010) Guideline for the diagnosis and management of osteoporosis in postmenopausal women and men of 50 years in the UK. National Osteoporosis Guideline Group (NOGG)
35.
go back to reference Kanis JA, Burlet N, Cooper C, Delmas PD, Reginster JY, Borgstrom F, Rizzoli R (2008) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 19:399–428PubMedCrossRef Kanis JA, Burlet N, Cooper C, Delmas PD, Reginster JY, Borgstrom F, Rizzoli R (2008) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 19:399–428PubMedCrossRef
36.
go back to reference Varenna M, Binelli L, Zucchi F, Ghiringhelli D, Gallazzi M, Sinigaglia L (1999) Prevalence of osteoporosis by educational level in a cohort of postmenopausal women. Osteoporos Int 9:236–241PubMedCrossRef Varenna M, Binelli L, Zucchi F, Ghiringhelli D, Gallazzi M, Sinigaglia L (1999) Prevalence of osteoporosis by educational level in a cohort of postmenopausal women. Osteoporos Int 9:236–241PubMedCrossRef
37.
go back to reference Cadarette SM, Gignac MA, Jaglal SB, Beaton DE, Hawker GA (2007) Access to osteoporosis treatment is critically linked to access to dual-energy X-ray absorptiometry testing. Med Care 45:896–901PubMedCrossRef Cadarette SM, Gignac MA, Jaglal SB, Beaton DE, Hawker GA (2007) Access to osteoporosis treatment is critically linked to access to dual-energy X-ray absorptiometry testing. Med Care 45:896–901PubMedCrossRef
38.
go back to reference Brask-Lindemann D, Cadarette SM, Eskildsen P, Abrahamsen B (2011) Osteoporosis pharmacotherapy following bone densitometry: importance of patient beliefs and understanding of DXA results. Osteoporos Int 22:1493–1501PubMedCrossRef Brask-Lindemann D, Cadarette SM, Eskildsen P, Abrahamsen B (2011) Osteoporosis pharmacotherapy following bone densitometry: importance of patient beliefs and understanding of DXA results. Osteoporos Int 22:1493–1501PubMedCrossRef
Metadata
Title
Hip fracture and other predictors of anti-osteoporosis drug use in Norway
Authors
H. M. Devold
A. J. Søgaard
A. Tverdal
J. A. Falch
K. Furu
H. E. Meyer
Publication date
01-04-2013
Publisher
Springer-Verlag
Published in
Osteoporosis International / Issue 4/2013
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-012-2063-1

Other articles of this Issue 4/2013

Osteoporosis International 4/2013 Go to the issue